Physician profile
Honling John Yuen
NPI 1508808825
$1,409.55
in general payments reported to CMS, 2019-2025
20 companies · $742 in 2025
The $742 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $14.77 · 2023: $458 · 2024: $194 · 2025: $742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,394.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $224.22 | 2023-2025 | Rybelsus, Wegovy, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.90 | 2023-2025 | Jardiance, Ofev, Jascayd |
| Exact Sciences Corporation | $189.53 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $161.34 | 2023-2025 | Vraylar |
| Glaxosmithkline, LLC. | $117.65 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $107.29 | 2023-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $63.29 | 2023-2025 | Mounjaro, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $47.17 | 2020-2023 | Eliquis, Camzyos |
| Pfizer INC. | $43.93 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.16 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $34.39 | 2023 | Livalo, Seglentis |
| Medtronic, INC. | $27.99 | 2023 | Intellis Adaptivestim |
| Philips North America LLC | $27.69 | 2024 | (Ck7) Extended Holter |
| Corcept Therapeutics | $25.16 | 2025 | Korlym |
| Dexcom, INC. | $23.80 | 2025 | Dexcom G6 Transmitter |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vbi Vaccine (Delaware) INC. | $22.53 | 2023 | Prehevbrio |
| Abbott Laboratories | $18.02 | 2023 | Freestyle Libre 3 |
| Astellas Pharma US INC | $15.62 | 2025 | Veozah |
| Xeris Pharmaceuticals, INC. | $14.98 | 2025 | Gvoke Hypopen |
| Tolmar, INC. | $14.89 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Honling Yuen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.